

Reference Number: FOIAH2425/154
From: Commercial
Date: 12 June 2024
Subject: Cancer Treatment using Specified Products

- Q1 In the past 6 months, what was the number of patients treated with a combination of Dabrafenib + Trametinib for the following conditions:
A) Metastatic Melanoma
B) Adjuvant Melanoma
C) BRAF mutated Lung Cancer
- A1 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.
- Q2 In the past 6 months, what was the number of patients treated with a combination of Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following conditions:
A) Metastatic Melanoma
B) Colorectal Cancer
- A2 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.